CollPlant Biotechnologies Ltd

Snapshot

CollPlant is a tiny biotech with $2.4M in FY 2025 revenue and a $11.5M net loss, funded mostly by a $8.2M R&D budget. It burned $9.4M in free cash flow against just $6.0M in cash, and the company itself has said that isn't enough to run for the next 12 months.

What's Happening Right Now

• Mon 31st Aug '26 · Acquisition: On August 31, 2026, CollPlant announced it is acquiring LightSolver, a photonic computing company, moving the company into supercomputing and photonic computing markets.
• Thu 13th Aug '26 · Reverse split: CollPlant is seeking shareholder approval for a reverse stock split of 1-for-8 to 1-for-12 after receiving a Nasdaq non-compliance notice in March 2026 for trading below the $1.00 minimum bid price.
• Wed 22nd Jul '26 · Going concern: CollPlant filed a prospectus supplement on July 22, 2026 warning it does not have enough cash to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• Fri 10th Jul '26 · Shelf filing: CollPlant filed an F-3 shelf registration on July 10, 2026 covering resale of over 31 million shares, disclosing insufficient cash to operate for 12 months and that it has begun evaluating strategic alternatives including acquisitions.
• Tue 30th Jun '26 · Private placement: On June 30, 2026, CollPlant priced a $2.6 million private placement of shares and warrants at $0.34 per share, with proceeds earmarked for general corporate purposes, R&D, and evaluating strategic combinations.